Seed round:
€2.5m total
50% equity
50% grants
>€100K tickets
Q4/26 closing
RIANA Therapeutics is currently raising a €2.5M seed round to advance our STAT5 inhibitor program to lead nomination. Having successfully secured Austrian non-dilutive public funding four times, we offer investors an unusually capital-efficient entry point: with co-financing rates of up to 60% at this stage, every euro invested carries the programmatic impact of two to three — without additional dilution. If you are an investor with an interest in early-stage oncology and first-in-class potential, we would welcome a conversation.
We are particularly interested in connecting with early-stage investors who bring not only capital but sector expertise — whether in oncology, drug discovery, or Austrian and European biotech ecosystems.
Ticket sizes starting at €100K are welcome at this stage. The round will be closed by November 2026.
Contact
Anna Orlova, CEO 📧 office@rianatx.com
RIANA Therapeutics 